CD274 and neoplasm: Traditional markers like PD-L1 expression have failed to predict response to nivolumab and pembrolizumab.547,548,638,639 Other potential biomarkers, such as high tumor mutational burden (TMB) or microsatellite instability (MSI), are limited in HCC.